Form 8-K - Current report:
SEC Accession No. 0001193125-25-261799
Filing Date
2025-11-03
Accepted
2025-11-03 09:14:11
Documents
11
Period of Report
2025-11-03
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K cgem-20251103.htm   iXBRL 8-K 58293
2 EX-99.1 cgem-ex99_1.htm EX-99.1 60471
  Complete submission text file 0001193125-25-261799.txt   237531

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT cgem-20251103.xsd EX-101.SCH 24922
13 EXTRACTED XBRL INSTANCE DOCUMENT cgem-20251103_htm.xml XML 4711
Mailing Address ONE MAIN STREET SUITE 1350 CAMBRIDGE MA 02142
Business Address ONE MAIN STREET SUITE 1350 CAMBRIDGE MA 02142 617-410-4650
Cullinan Therapeutics, Inc. (Filer) CIK: 0001789972 (see all company filings)

EIN.: 813879991 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39856 | Film No.: 251442347
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)